STCube, Inc. (KOSDAQ:052020)

Market Cap	1.05T +111.1%
Revenue (ttm)	6.98B -38.2%
Net Income	-21.80B
EPS	-321.00
Shares Out	67.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	275,278
Average Volume	685,367
Open	15,420
Previous Close	15,390
Day's Range	15,180 - 16,100
52-Week Range	5,500 - 20,200
Beta	-0.82
RSI	53.19
Earnings Date	May 14, 2026

About STCube

STCube, Inc., a biopharmaceutical company, develops medicines in South Korea. The company develops anti-cancer immunotherapeutic drugs and anti-viral drugs. It offers platform technologies, which include In vivo RNAi ICP target discovery platform for exploring material ICP target; glycosylation-specific antibody development platform for development of antibodies that mask glycosylation sites on target proteins; and ICP functional assay platform for development of various in vivo/in vitro analytical/experimental methods. The company’s product pi...

• Industry: Technology Distributors
• Sector: Technology
• Founded: 1989
• Employees: 13
• Stock Exchange: KOSDAQ
• Ticker Symbol: 052020

Financial Performance

In 2025, STCube's revenue was 6.98 billion, a decrease of -38.18% compared to the previous year's 11.30 billion. Losses were -21.80 billion, 1.69% more than in 2024.